ALZN — Alzamend Neuro Cashflow Statement
0.000.00%
Last trade - 00:00Annual cashflow statement for Alzamend Neuro, fiscal year end - April 30th, USD millions except per share, conversion factor applied.
2022 April 30th | 2023 April 30th | 2024 April 30th | 2025 April 30th | 2026 April 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -12.4 | -14.9 | -9.95 | -4.51 | -8.77 |
| Depreciation | |||||
| Non-Cash Items | 4.42 | 3.58 | 0.956 | 0.334 | 0.708 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 1.33 | 2.35 | 0.671 | -2.44 | -0.114 |
| Change in Prepaid Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Cash from Operating Activities | -6.61 | -8.92 | -8.27 | -6.57 | -8.07 |
| Capital Expenditures | -0.106 | 0 | -0.147 | -0.3 | 0 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0 | — | — | — | — |
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -0.106 | 0 | -0.147 | -0.3 | 0 |
| Financing Cash Flow Items | -0.059 | 0 | — | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 18.9 | 0 | 3.65 | 10.4 | 4.83 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 12.1 | -8.92 | -4.76 | 3.57 | -3.24 |